Diagnostic Imaging of Inflammatory Myopathies: New Concepts and a Radiological Approach

  • Júlio Brandão GuimarãesEmail author
  • Marcelo A. Nico
  • Alípio G. Omond
  • Laís Uyeda Aivazoglou
  • Rafael Baches Jorge
  • Edmar Zanoteli
  • Artur R. C. Fernandes
Imaging (D Mintz, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Imaging


Purpose of Review

The purpose of this review article is to highlight the current role of diagnostic imaging in the assessment of inflammatory myopathies.

Recent Findings

Recent research demonstrates that imaging plays an important role in evaluating patients with symptoms of an inflammatory myopathy. In general, MRI is the pivotal imaging modality for assessing inflammatory myopathies, revealing precise anatomic details because of changes in the signal intensity of the muscles. Whole-body MR imaging has become increasingly important over the last several years. US is also a valuable imaging modality for scanning muscles.


Together with the clinical history, familiarity with the imaging features of inflammatory myopathies is essential for formulating an accurate diagnosis.


Inflammatory myopathy Magnetic resonance imaging Whole-body magnetic resonance imaging Ultrasound 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    •• Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;373:393–4 In this study Dalaks provides a thorough description of the inflammatory muscle diseases. CrossRefGoogle Scholar
  2. 2.
    Murphy WA, Totty WG, Carroll JE. MRI of normal and pathologic skeletal muscle. AJR Am J Roentgenol. 1986;146:565–74.CrossRefGoogle Scholar
  3. 3.
    Wattjes MP, Kley RA, Fischer D. Neuromuscular imaging in inherited muscle diseases. Eur Radiol. 2010;20:2447–60.CrossRefGoogle Scholar
  4. 4.
    Lenk S, Fischer S, Kotter I, Claussen CD, Schlemmer HP. Possibilities of whole-body MRI for investigating musculoskeletal diseases. Radiologe. 2004;44:844–53.CrossRefGoogle Scholar
  5. 5.
    Filli L, Maurer B, Manoliu A, Andreisek G, Guggenberger R. Whole-body MRI in adult inflammatory myopathies: do we need imaging of the trunk? Eur Radiol. 2015;25:3499–507.CrossRefGoogle Scholar
  6. 6.
    Bashir WA, O’Donnell P. The myositides: the role of imaging in diagnosis and treatment. Semin Musculoskelet Radiol. 2010;14:217–26.CrossRefGoogle Scholar
  7. 7.
    Garcia J. MRI in inflammatory myopathies. Skelet Radiol. 2000;29:425–38.CrossRefGoogle Scholar
  8. 8.
    May DA, Disler DG, Jones EA, Balkissoon AA, Manaster BJ. Abnormal signal intensity in skeletal muscle at MR imaging: patterns, pearls, and pitfalls. Radiographics 2000;20 Spec No:S295–S315.Google Scholar
  9. 9.
    Van De Vlekkert J, Maas M, Hoogendijk JE, De Visser M, Van Schaik IN. Combining MRI and muscle biopsy improves diagnostic accuracy in subacute-onset idiopathic inflammatory myopathy. Muscle Nerve. 2015;51:253–8.CrossRefGoogle Scholar
  10. 10.
    Del Grande F, Carrino JA, Del Grande M, Mammen AL, Stine LC. Magnetic resonance imaging of inflammatory myopathies. Top Magn Reson Imaging. 2011;22:39–43.CrossRefGoogle Scholar
  11. 11.
    Boutry N, Hachulla E, Zanetti-Musielak C, Morel M, Demondion X, Cotten A. Imaging features of musculoskeletal involvement in systemic sclerosis. Eur Radiol. 2007;17:1172–80.CrossRefGoogle Scholar
  12. 12.
    Schick F. Whole-body MRI at high field: technical limits and clinical potential. Eur Radiol. 2005;15:946–59.CrossRefGoogle Scholar
  13. 13.
    Sookhoo S, Mackinnon I, Bushby K, Chinnery PF, Birchall D. MRI for the demonstration of subclinical muscle involvement in muscular dystrophy. Clin Radiol. 2007;62:160–5.CrossRefGoogle Scholar
  14. 14.
    Shelly MJ, Bolster F, Foran P, Crosbie I, Kavanagh EC, Eustace SJ. Whole-body magnetic resonance imaging in skeletal muscle disease. Semin Musculoskelet Radiol. 2010;14:47–56.CrossRefGoogle Scholar
  15. 15.
    •• Day J, Patel S, Limaye V. The role of magnetic resonance imaging techniques in evaluation and management of the idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2017;46:642–9 This study examines the role of MRI in evaluation of the idiopathic inflammatory myopathies and shows that MRI has a clear role in aiding diagnosis of these conditions, guiding muscle biopsy, differentiating subtypes a pattern-based approach, and monitoring disease activity in a longitudinal fashion. Also shows that whole body MRI is an emerging technique that offers several advantages over regional MRI. CrossRefGoogle Scholar
  16. 16.
    Adler RS, Garofalo G. Ultrasound in the evaluation of the inflammatory myopathies. Curr Rheumatol Rep. 2009;11:302–8.CrossRefGoogle Scholar
  17. 17.
    Connell DA, Schneider-Kolsky ME, Hoving JL, Malara F, Buchbinder R, Koulouris G, et al. Longitudinal study comparing sonographic and MRI assessments of acute and healing hamstring injuries. AJR Am J Roentgenol. 2004;183:975–84.CrossRefGoogle Scholar
  18. 18.
    Vilela VS, Prieto-Gonzalez S, Milisenda JC, Selva OCA, Grau JM. Polymyositis, a very uncommon isolated disease: clinical and histological re-evaluation after long-term follow-up. Rheumatol Int. 2015;35:915–20.CrossRefGoogle Scholar
  19. 19.
    Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology. 2008;70:418–24.CrossRefGoogle Scholar
  20. 20.
    Smitaman E, Flores DV, Gomez CM, Pathria MN. MR imaging of atraumatic muscle disorders. Radiographics. 2018;38:500–22.CrossRefGoogle Scholar
  21. 21.
    Huang ZG, Gao BX, Chen H, Yang MX, Chen XL, Yan R, et al. An efficacy analysis of whole-body magnetic resonance imaging in the diagnosis and follow-up of polymyositis and dermatomyositis. PLoS One. 2017;12:e0181069.CrossRefGoogle Scholar
  22. 22.
    Verschuuren J, Cox FM, van Engelen B, de Visser M, Badrising UA. Inflammatory myopathies. In: Wattjes MP, Fischer D, editors. Neuromuscular imaging. New York: Springer Science; 2013. p. 321–34.CrossRefGoogle Scholar
  23. 23.
    O’Connell MJ, Powell T, Brennan D, Lynch T, McCarthy CJ, Eustace SJ. Whole-body MR imaging in the diagnosis of polymyositis. AJR Am J Roentgenol. 2002;179:967–71.CrossRefGoogle Scholar
  24. 24.
    Tomasova SJ, Charvat F, Jarosova K, Vencovsky J. The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology. 2007;46:1174–9.CrossRefGoogle Scholar
  25. 25.
    Muro Y, Sugiura K, Akiyama M. Cutaneous manifestations in dermatomyositis: key clinical and serological features—a comprehensive review. Clin Rev Allergy Immunol. 2016;51:293–302.CrossRefGoogle Scholar
  26. 26.
    Engel AG, Hohlfeld R. The polymyositis and dermatomyositis complex. In: Engel AG, Franzini-Armstrong C, editors. Myology. New York: McGraw-Hill; 2008. p. 1335–83.Google Scholar
  27. 27.
    Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Bendo R, Gambari PF, et al. Anti-Mi-2 antibodies. Autoimmunity. 2005;38:79–83.CrossRefGoogle Scholar
  28. 28.
    Schulze M, Kotter I, Ernemann U, Fenchel M, Tzaribatchev N, Claussen CD, et al. MRI findings in inflammatory muscle diseases and their noninflammatory mimics. AJR Am J Roentgenol. 2009;192:1708–16.CrossRefGoogle Scholar
  29. 29.
    Zheng Y, Liu L, Wang L, Xiao J, Wang Z, Lv H, et al. Magnetic resonance imaging changes of thigh muscles in myopathy with antibodies to signal recognition particle. Rheumatology. 2015;54:1017–24.CrossRefGoogle Scholar
  30. 30.
    Pipitone N, Notarnicola A, Levrini G, Spaggiari L, Scardapane A, Iannone F, et al. Do dermatomyositis and polymyositis affect different thigh muscle groups? A comparative MRI-based study. Ann Rheum Dis. 74.Google Scholar
  31. 31.
    Hesla RB, Karlson LK, McCauley RG. Milk of calcium fluid collection in dermatomyositis: ultrasound findings. Pediatr Radiol. 1990;20:344–6.CrossRefGoogle Scholar
  32. 32.
    de Castro TC, Guarniero R, Giacomin MF, Meneghin MB, Martins GB, Lotufo Sde A. “Milk of calcium”: a rare presentation of calcinosis. Rev Bras Reumatol. 2014;54:65–7.CrossRefGoogle Scholar
  33. 33.
    Suzuki S, Nishikawa A, Kuwana M, Nishimura H, Watanabe Y, Nakahara J, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis. 2015;10:61.CrossRefGoogle Scholar
  34. 34.
    Watanabe Y, Uruha A, Suzuki S, Nakahara J, Hamanaka K, Takayama K, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016;87:1038–44.CrossRefGoogle Scholar
  35. 35.
    Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, Lahouti AH, Basharat P, Albayda J, et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis. 2017;76:681–7.CrossRefGoogle Scholar
  36. 36.
    Pelissou C, Lerolle N, Labeyrie C, Durand E, Besson FL. 18F-FDG PET/CT and MRI in necrotizing autoimmune myopathy: “the scarface sign”. Clin Nucl Med. 2018;43:147–9.CrossRefGoogle Scholar
  37. 37.
    Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018;20:21.CrossRefGoogle Scholar
  38. 38.
    Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin N Am. 2002;28:723–41.CrossRefGoogle Scholar
  39. 39.
    de Camargo LV, de Carvalho MS, Shinjo SK, de Oliveira ASB, Zanoteli E. Clinical, histological, and immunohistochemical findings in inclusion body myositis. Biomed Res Int. 2018;2018:5069042.CrossRefGoogle Scholar
  40. 40.
    Lloyd TE, Mammen AL, Amato AA, Weiss MD, Needham M, Greenberg SA. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014;83:426–33.CrossRefGoogle Scholar
  41. 41.
    Weihl CC, Mammen AL. Sporadic inclusion body myositis—a myodegenerative disease or an inflammatory myopathy. Neuropathol Appl Neurobiol. 2017;43:82–91.CrossRefGoogle Scholar
  42. 42.
    •• Guimaraes JB, Zanoteli E, Link TM, de Camargo LV, Facchetti L, Nardo L, et al. Sporadic inclusion body myositis: MRI findings and correlation with clinical and functional parameters. AJR Am J Roentgenol. 2017;209:1340–7 This study suggests that most patients with biopsy-proven sporadic IBM present with a typical pattern of muscle involvement at MRI and these findings strongly correlated with clinical and functional parameters. CrossRefGoogle Scholar
  43. 43.
    Tasca G, Monforte M, De Fino C, Kley RA, Ricci E, Mirabella M. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis. Muscle Nerve. 2015;52:956–62.CrossRefGoogle Scholar
  44. 44.
    Escola-Verge L, Pinal-Fernandez I, Fernandez-Codina A, Callejas-Moraga EL, Espinosa J, Marin A, et al. Mixed connective tissue disease and epitope spreading: an historical cohort study. J Clin Rheumatol. 2017;23:155–9.CrossRefGoogle Scholar
  45. 45.
    Trallero-Araguas E, Grau-Junyent JM, Labirua-Iturburu A, Garcia-Hernandez FJ, Monteagudo-Jimenez M, Fraile-Rodriguez G, et al. Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group. Semin Arthritis Rheum. 2016;46:225–31.CrossRefGoogle Scholar
  46. 46.
    Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Albayda J, Paik JJ, Johnson C, et al. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology. 2017;56:999–1007.CrossRefGoogle Scholar
  47. 47.
    Noguchi E, Uruha A, Suzuki S, Hamanaka K, Ohnuki Y, Tsugawa J, et al. Skeletal muscle involvement in antisynthetase syndrome. JAMA Neurol. 2017;74:992–9.CrossRefGoogle Scholar
  48. 48.
    Andersson H, Kirkhus E, Garen T, Walle-Hansen R, Merckoll E, Molberg O. Comparative analyses of muscle MRI and muscular function in anti-synthetase syndrome patients and matched controls: a cross-sectional study. Arthritis Res Ther. 2017;19:17.CrossRefGoogle Scholar
  49. 49.
    Wattjes MP, Fischer D. Neuromuscular imaging. Berlin: Springer; 2013.CrossRefGoogle Scholar
  50. 50.
    Dalakas MC. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry. 2009;80:832–8.CrossRefGoogle Scholar
  51. 51.
    Pasnoor M, Barohn RJ, Dimachkie MM. Toxic myopathies. Curr Opin Neurol. 2018;31:575–82.PubMedGoogle Scholar
  52. 52.
    Pasnoor M, Barohn RJ, Dimachkie MM. Toxic myopathies. Neurol Clin. 2014;32:647–70 viii.CrossRefGoogle Scholar
  53. 53.
    Mammen AL. Toxic myopathies. Continuum. 2013;19:1634–49.PubMedGoogle Scholar
  54. 54.
    Shulman LE. Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome? J Rheumatol. 1984;11:569–70.PubMedGoogle Scholar
  55. 55.
    Helfman T, Falanga V. Eosinophilic fasciitis. Clin Dermatol. 1994;12:449–55.CrossRefGoogle Scholar
  56. 56.
    Doyle JA, Ginsburg WW. Eosinophilic fasciitis. Med Clin N Am. 1989;73:1157–66.CrossRefGoogle Scholar
  57. 57.
    Moulton SJ, Kransdorf MJ, Ginsburg WW, Abril A, Persellin S. Eosinophilic fasciitis: spectrum of MRI findings. AJR Am J Roentgenol. 2005;184:975–8.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Júlio Brandão Guimarães
    • 1
    • 2
    • 3
    Email author
  • Marcelo A. Nico
    • 1
    • 4
  • Alípio G. Omond
    • 1
  • Laís Uyeda Aivazoglou
    • 1
    • 2
  • Rafael Baches Jorge
    • 1
    • 4
  • Edmar Zanoteli
    • 5
  • Artur R. C. Fernandes
    • 2
  1. 1.Department of Radiology, Grupo OsteomuscularFleury Medicina e SaúdeSão PauloBrazil
  2. 2.Department of Radiology, Escola Paulista de MedicinaFederal University of Sao Paulo (UNIFESP)São PauloBrazil
  3. 3.Department of Radiology and Biomedical ImagingUniversity of CaliforniaSan FranciscoUSA
  4. 4.Division of Musculoskeletal, Department of RadiologySanta Casa de Misericórdia de São PauloSão PauloBrazil
  5. 5.Department of NeurologyFaculdade de Medicina (FMUSP), Universidade de São PauloSão PauloBrazil

Personalised recommendations